Nexviadyme®▼ (avalglucosidase alfa) safety profile
Find out more about the safety and tolerability profile for Nexviadyme®.
This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.
Find out more about the safety and tolerability profile for Nexviadyme®.
Explore the results and evidence supporting Nexviadyme® and how it was studied through several clinical trials.
Explore the results and evidence supporting Fabrazyme® and how it was studied through several clinical trials.
Recording from Paradigm 2024
Recording from Paradigm 2024
Recording from Paradigm 2024
MAT-XU-2305062 (v1.0) - Date of preparation: November 2023